BACKGROUND Valvular heart disease (VHD) and atrial fibrillation (AF) often coexist. Phase III trials comparing
to be at particularly high thromboembolic risk (5)-have been consistently exclusion criteria for the phase III trials comparing the nonvitamin K antagonist oral anticoagulants (NOACs) with warfarin (6) (7) (8) (9) . One phase II trial testing the direct thrombin inhibitor dabigatran etexilate in patients with mechanical prosthetic valves was prematurely terminated because of excess stroke in the dabigatran arm at doses also associated with excess bleeding (10) . In these patients, therefore, vitamin K antagonists (VKAs) are currently the only recommended oral anticoagulants for the prevention of SSEE (11) (12) (13) , whereas NOAC data on AF and mitral stenosis are lacking. 
METHODS
The present meta-analysis was planned, conducted, and reported in accordance with currently available statements for design, analysis, and reporting of meta-analyses of randomized and observational studies (18, 19) .
SEARCH STRATEGY AND SELECTION CRITERIA. We searched PubMed, the U.S. National Institutes of Health Clinical Trials Registry (Clinicaltrials.gov), the Cochrane Library, Web of Science, as well as abstracts from major cardiology societies' meetings. Search terms used were "dabigatran" OR "rivaroxaban" OR "apixaban" "OR "edoxaban" AND "warfarin" AND "atrial fibrillation" AND "valvular heart disease".
We also searched websites, including theheart.org, escardio.org, and ResearchGate, for relevant mate- We performed a first pre-specified, trial-based analysis aimed at comparing primary efficacy and safety outcomes as stratified by VHD status and randomized treatment in the 4 phase III RCTs comparing efficacy and safety of NOACs with warfarin for stroke prevention in patients with AF (6-9). Data were collected from the 3 published post hoc analyses of RE-LY (14) , ROCKET AF (15) , and ARISTOTLE (16), through personal communication, and through a joint work with the principal investigator (R.P.G.) of ENGAGE AF-TIMI 48 (17) , who is a co-author of this paper.
Outcomes of interest for the current meta-analysis were stroke or SSEE, major bleeding, intracranial hemorrhage (ICH), and all-cause death. Ischemic stroke alone was considered in patients from the 
RESULTS
We identified 4 studies with the predefined selection criteria, with an overall population of 13,585 patients with VHD from a total population of 71,683 patients ( Figure 1 ). Compared with patients without VHD, patients with VHD were on average at higher risk because they were older, had more sustained forms of AF, had higher rate of heart failure history and of coronary artery disease, and higher congestive heart failure, hypertension (CHADS 2 ) scores (with the exception of patients from ROCKET AF). Table 2 reports the frequency of VHD subtypes in patients randomized in the 4 trials.
In a total of 13,585 patients with VHD included in this main analysis, we found a similar rate of SSEE (Figure 3) . For these outcomes, we found no significant statistical heterogeneity among studies.
Finally, we performed an analysis including all NOAC dose arms studied against warfarin. Also, in this case, we considered SSEE major bleeding, ICH, and all-cause death. The results are substantially similar to those restricted to the higher dose NOACs.
Inclusion of the lower doses of dabigatran and edoxaban decreased the magnitude of the risk reduction for SSEE with NOACs versus warfarin and resulted in less major bleeding than warfarin both in patients with and without VHD (Online Figures 3A and 3B ), as consistently shown by the jackknife sensitivity analysis omitting higher or lower doses of dabigatran and edoxaban together (Online Table 1 ). Similarly to major bleeding, the risk reduction of ICH by NOACs versus warfarin was slightly amplified after the inclusion of the lower doses in the analysis, but ICH was reduced consistently both in VHD and no-VHD patients (Online Figure 4A) . Conversely, the inclusion of lower doses did not modify the relative risk of all-cause death (Online Figure 4B ).
Sensitivity analyses showed that some studies significantly affected the pooled RRs for SSEE and major bleeding (Online Table 2 Table 2 ).
Qualitatively, the overall risk of reporting bias was low according to the Cochrane Collaboration Tool classification (26) (Online Figure 5) .
DISCUSSION
The present meta-analysis suggests that, compared with patients with AF without VHD, patients with AF and VHD: 1) were on average at higher risk (they were older, had more frequently sustained AF, had a higher prevalence of heart failure and coronary artery disease, and a higher CHADS 2 score); and 2) had higher rates of major bleeding and all-cause death.
The present meta-analysis also however indicates that 3) the efficacy and safety of NOACs versus Values are n (%). *These patients were analyzed with the No-VHD group because the VHD definition adopted always included at least "moderate" VHD. †Biologic prosthetic valves also excluded.
NR ¼ not reported; other abbreviations as in Table 1 . As shown in Table 1 Forest plot with individual and summary estimates of the relative risk (RR) and 95% confidence interval (CI) of stroke/SEE and major bleeding for higher-dose NOACs versus warfarin among patients without and with VHD, separately and overall. A random-effect model was applied to estimate RR and 95% CI. Squares and diamond sizes are proportional to study weight. Inter-study heterogeneity, separately reported for no-VHD and VHD groups, and for the overall population, was tested using
Cochran's Q test (see text for details). The figure shows that the relative efficacy and safety of NOACs versus warfarin as to the main efficacy (stroke/SEE) and safety (major bleeding) endpoints are similar in no-VHD and VHD patients. CI ¼ confidence interval; IV ¼ inverse variance; NOAC ¼ non-vitamin K antagonist oral anticoagulant; RR ¼relative risk; SEE ¼ systemic embolic events; VHD ¼ valvular heart disease.
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CONCLUSIONS
In patients with AF and VHD (other than moderate/ severe mitral stenosis or mechanical heart valves)
NOACs are attractive alternatives to VKAs because the coexistence of VHD does not affect the overall relative efficacy or safety of NOACs in terms of Forest plot with individual and summary estimates of the RR and 95% CI of all-cause death for higher dose NOACs versus warfarin among patients without and with VHD, separately and overall. A random-effect model was applied to estimate RR and 95% CI. Squares and diamond sizes are proportional to study weight. Inter-study heterogeneity, separately reported for no-VHD and VHD groups, and for the overall population, was tested using Cochran's Q test (see text for details). Abbreviations as in Figure 2 .
